Is cytoreductive surgery and hyperthermic intraperitoneal chemotherapy indicated in hepatobiliary malignancies?

BACKGROUND: Hepatopancreaticobiliary malignancies with peritoneal carcinomatosis exhibit poor survival with current therapies: hepatocellular carcinoma 11 months with sorafenib, and pancreaticobiliary 9–14 months with systemic chemotherapy. However, limited data exist on the utility of cytoreductive...

Descripción completa

Detalles Bibliográficos
Autores principales: Leigh, Natasha, Solomon, Daniel, Pletcher, Eric, Labow, Daniel M., Magge, Deepa R., Sarpel, Umut, Golas, Benjamin J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291534/
https://www.ncbi.nlm.nih.gov/pubmed/32527272
http://dx.doi.org/10.1186/s12957-020-01898-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291534/
https://www.ncbi.nlm.nih.gov/pubmed/32527272
http://dx.doi.org/10.1186/s12957-020-01898-5

Ejemplares similares